跳至主要内容
临床试验/NCT03140358
NCT03140358进行中(未招募)3 期

The Use of Atropine 0.01% in the Prevention and Control of Myopia (ATOM3)

Singapore National Eye Centre1 个研究点 分布在 1 个国家目标入组 300 人开始时间: 2017年4月21日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
3 期
状态
进行中(未招募)
入组人数
300
试验地点
1
主要终点
Spherical Equivalent

研究概览

简要总结

Study of low dose atropine in preventing the onset and progression of myopia in high risk children with pre-myopia or low-myopia.

详细描述

High risk children (with family history of myopia) with low hyperopia or low myopia will be randomized to atropine or placebo, with 2 -2.5 year treatment and 1 year washout.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
5 Years 至 9 Years(Child)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • Any eye or systemic disease that affect vision or refractive error
  • Conditions where topical atropine contraindicated
  • Previous use of atropine or pirenzepine
  • Known past/current amblyopia or strabismus

研究组 & 干预措施

Low myopia atropine

Active Comparator

On Atropine 0.01% daily or every other day

干预措施: Atropine sulfate 0.01% (Drug)

Premyopia atropine

Active Comparator

On Atropine 0.01%

干预措施: Atropine sulfate 0.01% (Drug)

Premyopia placebo

Placebo Comparator

On placebo

干预措施: Placebo (Drug)

Low myopia placebo

Placebo Comparator

On placebo

干预措施: Placebo (Drug)

结局指标

主要结局

Spherical Equivalent

时间窗: 3.5 years

SE

次要结局

  • Axial Length(3.5 years)

研究者

申办方类型
Other Gov
责任方
Principal Investigator
主要研究者

Audrey Chia Wei-Lin

Adjuct Associate Professor

Singapore National Eye Centre

研究点 (1)

Loading locations...

相似试验